

Angus HSCP Sep - Nov 2018		Top 50 GIC versus 2017		
Drug Name	Total GIC Paid	Spend reduction vs 2017	% reduction	Plan
EDOXABAN**	166,000	-12,094	-8%	Expected increase as move from other DOACs (excludes rebate)
BECLOMETASONE DIPROPIONATE AND FORMOTEROL FUMARATE (Fostair)**	142,935	1,026	1%	Stable prescribing after move from Seretide®
ENTERAL NUTRITION	107,800	20,779	16%	ONS transformation continuing 2019. PONMAG review begins May 19
QUETIAPINE	106,038	41,240	28%	More stable tariff price. Consideration for increased branded prescribing for MR to reduce dispensing error
CATHETERS - URETHRAL	93,246	-6,723	-8%	Concerning increase and PONMAG review began Sept 18 and is ongoing
BLOOD GLUCOSE TESTING STRIPS	92,015	-3,045	-3%	PONMAG review begins Nov 18. ? Freestyle consumables cost
LEVOTHYROXINE SODIUM	79,122	2,696	3%	Stable prescribing
WOUND MANAGEMENT DRESSINGS	63,439	24,195	28%	Ongoing PMG/PONMAG review. PONMAG review begins March 19
GLYCOPYRRONIUM BROMIDE	61,478	-1,285	-2%	Expected increase - switch from Non-formulary choice (Spiriva® Handihaler)
VENLAFAXINE	60,812	-8,416	-16%	Evadis price error correction Nov 18
RIVAROXABAN	56,126	85,608	60%	Expected decrease with move to Edoxaban
FOODS FOR SPECIAL DIETS (Neocate®/Nutramigen® etc)	55,132	10,010	15%	Under PONMAG review (started Sept 18) - more to go here
COLOSTOMY BAGS	52,671	-8,128	-18%	PONMAG review began Jan 19
PARACETAMOL	50,784	2,129	4%	Pts continue to source themselves from public campaign. Also polypharmacy reviews
EMPAGLIFLOZIN	48,005	-9,836	-26%	Diabetes pathway review pending
TACROLIMUS	46,413	3,579	7%	Switch from Prograf® to Adoport® started
INSULIN ASPART	46,277	-288	-1%	Diabetes pathway review pending
LEVETIRACETAM	45,806	16,286	26%	Reduction in SDT Price
ILEOSTOMY BAGS	44,646	2,456	5%	PONMAG review began Jan 19
LIRAGLUTIDE	44,145	-1,216	-3%	Diabetes pathway review pending
LIDOCAINE	44,062	15,357	26%	Continued discontinuation by Angus GPs GP review in Angus HSCP (started Sept 18) Polypharmacy reviews helping reduce use
LIOETHYRONINE SODIUM	43,660	23,712	35%	Expected fall with GP review
CO-CODAMOL	43,627	3,621	8%	Patent ends July 19. Passed to J Murray/PSU for generic switch 31 Oct 18
SOLIFENACIN	43,300	16,177	27%	Small decrease as move to Qvar®. Previously passed to Maureen Fagan & Arlene Shaw 31 Oct 18
BECLOMETASONE DIPROPIONATE (QVAR®/CLENIL®)	42,205	2,777	6%	Expected decrease with move to Edoxaban
APIXABAN	41,373	37,755	48%	Move away from Pentasa®.
MESALAZINE	40,789	2,970	7%	Passed to Craig Mowat 30/10/18 to review figures again
NAPROXEN	40,034			New to top 50 GIC. Expected with increase cost with shortage
PREGABALIN	39,737	161,362	80%	Expected decrease. Tariff price reduction.
HYDROCORTISONE	38,467	497	1%	Small increase. Passed to J Murray to confirm all patients on most cost effective form
INSULIN GLARGINE	38,153	8,304	18%	Diabetes pathway review pending
METFORMIN HYDROCHLORIDE	37,986	708	2%	Diabetes pathway review pending
LAMOTRIGINE**	37,745	7,356	16%	New to top 50 GIC last quarter. Passed to J Murray to assure all on most cost effective form
TRAMADOL HYDROCHLORIDE	37,395	4,501	11%	Improved GP reviews. Pending switch to branded generic Marol® for MR.
SALMETEROL WITH FLUTICASONE PROPIONATE (SERETIDE®)	35,698	64,422	64%	Expected reduction with Fostair® switch. Passed to Maureen Fagan & Arlene Shaw to help review 31 Oct 18
ATORVASTATIN	34,216	-1,264	-4%	Increased in use as first line
MELATONIN	32,110	1,375	4%	GP reviews in last quarter
TAMSULOSIN HYDROCHLORIDE**	32,016	-600	0%	Stable prescribing
ALOGLIPTIN	31,441			New to top 50 GIC. Expected with move from other DPP4s
OMEPRAZOLE	31,042	7,211	19%	GP de-prescribing HSCP supported project
CALCIUM WITH VITAMIN D	31,029	942	3%	Small decrease, likely over prescribing. Prescribing plan 2019
METHYLPHENIDATE HYDROCHLORIDE	30,863	6,865	18%	Expected reduction with move to Xaggitin® from Concertra®
GABAPENTIN	30,485	45,877	60%	SDT price decrease and de-prescribing
EYE PRODUCTS**	30,457	-350	-1%	Increase in use from optometrist requests. Will get review to ensure all formulary choices by J Murray.
OXYCODONE	29,532	5,738	16%	Expected decrease with GP switch to Longtec®/Shortec®
PROPRANLOL HYDROCHLORIDE**	28,554	1,029	3%	New in top 50 due to lower overall costs last quarter. Will begin to review. Stable prescribing
SALBUTAMOL**	28,334	-2	0%	Marked reduction with ongoing moves to more cost effective options.
EMOLLIENTS	28,203	16,409	37%	Pending technical switches 2019
TRIMIPRAMINE	27,535			New in top 50 due to lower overall costs last quarter. Will begin to review. Non-formulary
TIOTROPIUM	27,283	33,742	55%	Expected change in switch from Spiriva® to Seebri®. Passed to Maureen Fagan & Arlene Shaw to review 31 Oct 18
TOTAL		2,571,150		
Reduction in past 3 months		133,913	5%	
Reduction in past 12 months		576,793	18%	

** Drugs not in top 50 GIC last year, compared instead against last quarter

KEY:

Spend going up

Spend the same

Spend going down